Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study
Kumar H., Ha DH., Lee EJ., Park JH., Shim JH., Ahn TK.
Clinical Trial with a reported sample of 5 on Back Pain, Disc Degeneration, Immune Modulation, published in Stem Cell Res Ther (2017) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Stem Cell Res Ther (2017)
- Country
- England
- Reported sample size
- 5
- Source database
- PubMed
- PMID
- 29141662
- PMCID
- PMC5688755
- DOI
- 10.1186/s13287-017-0710-3
- NCT
- NCT02338271
- Citations
- 148
Abstract (original English)
Background Adipose tissue-derived mesenchymal stem cells (AT-MSCs) offer potential as a therapeutic option for chronic discogenic low back pain (LBP) because of their immunomodulatory functions and capacity for cartilage differentiation. The goal of this study was to assess the safety and tolerability of a single intradiscal implantation of combined AT-MSCs and hyaluronic acid (HA) derivative in patients with chronic discogenic LBP. Methods We performed a single-arm phase I clinical trial with a 12-month follow-up and enrolled 10 eligible chronic LBP patients. Chronic LBP had lasted for more than 3 months with a minimum intensity of 4/10 on a visual analogue scale (VAS) and disability level ≥ 30% on the Oswestry Disability Index (ODI). The 10 patients underwent a single intradiscal injection of combined HA derivative and AT-MSCs at a dose of 2 × 10 7 cells/disc (n = 5) or 4 × 10 7 cells/disc (n = 5). Safety and treatment outcomes were evaluated by assessing VAS, ODI, Short Form-36 (SF-36), and imaging (lumbar spine X-ray imaging and MRI) at regular intervals over 1 year. Results No patients were lost at any point during the 1-year clinical study. We observed no procedure or stem cell-related adverse events or serious adverse events during the 1-year follow-up period. VAS, ODI, and SF-36 scores significantly improved in both groups receiving both low (cases 2, 4, and 5) and high
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level ASystematic ReviewEurope PMC
Role of Platelet-Rich Plasma (PRP) in the Management of Stage III and IV Degenerative Disc Disease
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Cureus (2025) — summary generated from the PubMed abstract.
- 2025
Cureus1 citations - Level ASystematic ReviewPubMed
Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from the American Society Of Interventional Pain Physicians (ASIPP).
Systematic Review on Back Pain, Scar, published in Pain Physician (2025) — summary generated from the PubMed abstract.
- 2025
Pain Physician - Level AMeta-analysisPubMed
Mesenchymal Stromal Cells for the Treatment of Discogenic Low Back Pain: A Systematic Review of Clinical Studies.
Meta-analysis with a reported sample of 736 on Back Pain, Disc Degeneration, published in Neurospine (2025) — summary generated from the PubMed abstract.
- 2025
- n = 736
Neurospine1 citations - Level ASystematic ReviewEurope PMC
Sirtuins in intervertebral disc degeneration: current understanding
Systematic Review on Back Pain, Disc Degeneration, Chronic Inflammation, published in Mol Med (2024) — summary generated from the PubMed abstract.
- 2024
Mol Med11 citations - Level ASystematic ReviewEurope PMC
A comprehensive review of cell transplantation and platelet-rich plasma therapy for the treatment of disc degeneration-related back and neck pain: A systematic evidence-based analysis
Systematic Review on Back Pain, Disc Degeneration, published in JOR Spine (2024) — summary generated from the PubMed abstract.
- 2024
JOR Spine22 citations